Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort.

Autor: Vegh Z; First Department of Medicine, Semmelweis University, Budapest, Hungary veghzsuzsi@gmail.com., Burisch J; Gastrounit, Medical Section, Hvidovre University Hospital, Hvidovre, Denmark., Pedersen N; Gastroenterology Department, Slagelse University Hospital, Slagelse, Denmark., Kaimakliotis I; Nicosia private practice, Cyprus., Duricova D; IBD Centre ISCARE, Charles University, Prague, Czech Republic., Bortlik M; IBD Centre ISCARE, Charles University, Prague, Czech Republic., Vinding KK; Digestive Disease Centre, Medical Section, Herlev University Hospital, Copenhagen, Denmark., Avnstrøm S; Department of Medicine, Amager Hospital, Amager, Denmark., Olsen J; Medical Department, National Hospital of the Faroe Islands, Torshavn, Faroe Islands., Nielsen KR; Medical Department, National Hospital of the Faroe Islands, Torshavn, Faroe Islands., Katsanos KH; First Division of Internal Medicine and Division of Gastroenterology, Faculty of Medicine, University of Ioannina, Ioannina, Greece., Tsianos EV; First Division of Internal Medicine and Division of Gastroenterology, Faculty of Medicine, University of Ioannina, Ioannina, Greece., Lakatos L; Department of Medicine, Csolnoky F. Province Hospital, Veszprem, Hungary., Schwartz D; First Department of Medicine, Semmelweis University, Budapest, Hungary., Odes S; Department of Gastroenterology and Hepatology, Soroka Medical Centre and Ben-Gurion University of the Negev, Beer Sheva, Israel., D'Incà R; UO Gastroenterologia, Azienda Ospedaliera-Università di Padova, Padova, Italy On behalf of the EpiCom Northern Italy centre based in Crema, Cremona, Firenze, Forlì & Padova and Reggio Emilia, Italy., Beltrami M; Degenza Breve Internistica e Centro M.I.C.I.-Azienda Ospedaliera Arcispedale S Maria Nuova, Reggio Emilia, Italy On behalf of the EpiCom Northern Italy centre based in Crema, Cremona, Firenze, Forlì & Padova and Reggio Emilia, Italy., Kiudelis G; Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania., Kupcinskap L; Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania., Jucov A; Department of Gastroenterology, State University of Medicine and Pharmacy, Chisinau, Republic of Moldova., Turcan S; Department of Gastroenterology, State University of Medicine and Pharmacy, Chisinau, Republic of Moldova., Barros LF; Hospital de Vale de Sousa, Porto, Portugal., Magro F; Department of Gastroenterology, Hospital de São João, Porto, Portugal Department of Pharmacology and Therapeutics, Oporto Medical School, Porto, Portugal MedInUP-Centre for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal., Lazar D; Clinic of Gastroenterology, University of Medicine 'Victor Babes', Timisoara, Romania., Goldis A; Clinic of Gastroenterology, University of Medicine 'Victor Babes', Timisoara, Romania., de Castro L; Department of Gastroenterology, Grupo de Investigación en Patología Digestiva, Instituto de Investigación Biomedica [IBI], Xerencia de Xestión Integrada de Vigo, SERGAS, Vigo, Spain., Hernandez V; Department of Gastroenterology, Grupo de Investigación en Patología Digestiva, Instituto de Investigación Biomedica [IBI], Xerencia de Xestión Integrada de Vigo, SERGAS, Vigo, Spain., Niewiadomski O; Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia., Bell S; Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia., Langholz E; Department C, Gastroenterology Section, Herlev and Gentofte Hospital, Hellerup, Denmark., Munkholm P; Gastro Unit, Medical Section, North Zealand Hospital, University of Copenhagen, Denmark., Lakatos PL; First Department of Medicine, Semmelweis University, Budapest, Hungary.
Jazyk: angličtina
Zdroj: Journal of Crohn's & colitis [J Crohns Colitis] 2015 Sep; Vol. 9 (9), pp. 747-53. Date of Electronic Publication: 2015 Jun 07.
DOI: 10.1093/ecco-jcc/jjv099
Abstrakt: Background and Aims: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis.
Methods: Nine Western, five Eastern European centres and one Australian centre with 258 Crohn's disease [CD], 380 ulcerative colitis [UC] and 71 IBD unclassified [IBDU] patients [female/male: 326/383; mean age at diagnosis: 40.9 years, SD: 17.3 years] participated. Patients' data were registered and entered in the web-based ECCO-EpiCom database [www.epicom-ecco.eu].
Results: In CD, 36 [19%] Western Europe/Australian and 6 [9%] Eastern European patients received biological therapy [p = 0.04], but the immunosuppressive [IS] use was equal and high in these regions [Eastern Europe vs Western Europe/Australia: 53% vs 45%; p = 0.27]. Surgery was performed in 17 [24%] CD patients in Eastern Europe and 13 [7%] in Western Europe/Australia [p < 0.001, pLogRank = 0.001]. Of CD patients from Eastern Europe, 24 [34%] were hospitalized, and 39 [21%] from Western Europe/Australia, [p = 0.02, pLogRank = 0.01]. In UC, exposure to biologicals and colectomy rates were low and hospitalization rates did not differ between these regions during the 1-year follow-up period [16% vs 16%; p = 0.93].
Conclusions: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CD patients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CD patients were treated with biologicals in the Western Europe/Australian centres.
(Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze: MEDLINE
Externí odkaz: